Hypertriglyceridemia
211
16
25
145
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
45 trials with published results (21%)
Research Maturity
145 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.6%
14 terminated out of 211 trials
91.2%
+4.7% vs benchmark
30%
64 trials in Phase 3/4
31%
45 of 145 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 145 completed trials
Clinical Trials (211)
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
A Study to Assess the Safety, Tolerability and Efficacy of ION775
A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque
A Study of SHR-1918 In Participants With Hypertriglyceridemia
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
RBD5044 in Chinese Participants With Hypertriglyceridemia
WB-EMS Effects on Cardiometabolic Risk Factors
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition
Russian Extreme Hypertriglyceridemia Registry
Single-ascending Dose Study of Kylo-12 in Healthy Subjects
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia